Share-based Payment Arrangement, Expense of BioCardia, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BioCardia, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • BioCardia, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $77,000, a 56% decline year-over-year.
  • BioCardia, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $521,000, a 30% decline year-over-year.
  • BioCardia, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $741,000, a 28% decline from 2023.
  • BioCardia, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,030,000, a 13% decline from 2022.
  • BioCardia, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,183,000, a 29% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BioCardia, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $521,000 $77,000 -$100,000 -56% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $621,000 $98,000 -$86,000 -47% 01 Apr 2025 30 Jun 2025 10-Q/A 29 Oct 2025 2025 Q2
Q1 2025 $707,000 $170,000 -$34,000 -17% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $741,000 $176,000 -$8,000 -4.3% 01 Oct 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
Q3 2024 $749,000 $177,000 -$74,000 -29% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $823,000 $184,000 -$133,000 -42% 01 Apr 2024 30 Jun 2024 10-Q/A 29 Oct 2025 2025 Q2
Q1 2024 $956,000 $204,000 -$74,000 -27% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $1,030,000 $184,000 -$96,000 -34% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
Q3 2023 $1,126,000 $251,000 -$29,000 -10% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $1,155,000 $317,000 +$13,000 +4.3% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $1,142,000 $278,000 -$41,000 -13% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $1,183,000 $280,000 -$144,000 -34% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $1,327,000 $280,000 -$157,000 -36% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $1,484,000 $304,000 -$80,000 -21% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $1,564,000 $319,000 -$97,000 -23% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $1,661,000 $424,000 -$195,000 -32% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $1,856,000 $437,000 -$300,000 -41% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $2,156,000 $384,000 -$271,000 -41% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $2,427,000 $416,000 -$525,000 -56% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $2,952,000 $619,000 +$207,000 +50% 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
Q3 2020 $2,745,000 $737,000 -$19,000 -2.5% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $2,764,000 $655,000 -$41,000 -5.9% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $2,805,000 $941,000 +$251,000 +36% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $412,000 -$279,000 -40% 29 Jan 2020 10-K 29 Mar 2022 2021 FY
Q3 2019 $2,833,000 $756,000 +$26,000 +3.6% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $2,807,000 $696,000 -$42,000 -5.7% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $2,849,000 $690,000 +$75,000 +12% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $2,774,000 $691,000 -$17,000 -2.4% 01 Oct 2018 31 Dec 2018 10-K 09 Apr 2020 2019 FY
Q3 2018 $2,791,000 $730,000 +$29,000 +4.1% 01 Jul 2018 30 Sep 2018 10-Q 19 Nov 2019 2019 Q3
Q2 2018 $2,762,000 $738,000 +$62,000 +9.2% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $2,700,000 $615,000 -$7,000 -1.1% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q4 2017 $2,707,000 $708,000 -$89,000 -11% 01 Oct 2017 31 Dec 2017 10-K 09 Apr 2020 2019 FY
Q3 2017 $2,796,000 $701,000 +$614,000 +706% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,182,000 $676,000 +$648,000 +2314% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $1,534,000 $622,000 +$592,000 +1973% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $942,000 $797,000 01 Oct 2016 31 Dec 2016 10-K 02 Apr 2019 2018 FY
Q3 2016 $87,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $28,000 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $30,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1

BioCardia, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $741,000 -$289,000 -28% 01 Jan 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
2023 $1,030,000 -$153,000 -13% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
2022 $1,183,000 -$478,000 -29% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $1,661,000 -$1,291,000 -44% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $2,952,000 +$230,000 +8.4% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $2,722,000 -$52,000 -1.9% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2021 2020 FY
2018 $2,774,000 +$67,000 +2.5% 01 Jan 2018 31 Dec 2018 10-K 09 Apr 2020 2019 FY
2017 $2,707,000 +$1,765,000 +187% 01 Jan 2017 31 Dec 2017 10-K 09 Apr 2020 2019 FY
2016 $942,000 +$659,000 +233% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2019 2018 FY
2015 $283,000 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.